The second group of ICIs is anti-PD-L1 antibodies, including atezolizumab, durvalumab, and avelumab, which block the ligand for PD-1-PD-L1-on tumor cells and on tumor-infiltrating immune cells [6,7,8]. The gene discussed is CD274; the disease is neoplasm.